CA2848724A1 - Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer - Google Patents

Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer Download PDF

Info

Publication number
CA2848724A1
CA2848724A1 CA2848724A CA2848724A CA2848724A1 CA 2848724 A1 CA2848724 A1 CA 2848724A1 CA 2848724 A CA2848724 A CA 2848724A CA 2848724 A CA2848724 A CA 2848724A CA 2848724 A1 CA2848724 A1 CA 2848724A1
Authority
CA
Canada
Prior art keywords
nhc
amino
compound
phenyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2848724A
Other languages
English (en)
Inventor
Arthur Decillis
Rodrigo RUIZ SOTO
Gary Thomas Emmons
Joanne LAGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Exelixis Inc
Original Assignee
Sanofi SA
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA, Exelixis Inc filed Critical Sanofi SA
Publication of CA2848724A1 publication Critical patent/CA2848724A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2848724A 2011-09-14 2012-09-14 Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer Abandoned CA2848724A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US61/534,836 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US61/543,529 2011-10-05
US201161562670P 2011-11-22 2011-11-22
US61/562,670 2011-11-22
PCT/US2012/055387 WO2013040337A1 (fr) 2011-09-14 2012-09-14 Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2848724A1 true CA2848724A1 (fr) 2013-03-21

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2848724A Abandoned CA2848724A1 (fr) 2011-09-14 2012-09-14 Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer

Country Status (10)

Country Link
EP (1) EP2755654A1 (fr)
KR (1) KR20140077911A (fr)
AU (1) AU2012308414A1 (fr)
BR (1) BR112014005858A2 (fr)
CA (1) CA2848724A1 (fr)
IL (1) IL231448A0 (fr)
IN (1) IN2014CN02671A (fr)
TW (1) TW201325592A (fr)
UY (1) UY34339A (fr)
WO (1) WO2013040337A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (zh) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 一种连续流微反应器中制备沙库巴曲中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
EP2322523B1 (fr) 2005-10-07 2019-01-02 Exelixis, Inc. Procédé de préparation d'inhibiteurs de PI3Kalpha de type pyridopyrimidinone
AU2006302179C1 (en) * 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2007044481A1 (fr) 2005-10-07 2007-04-19 Basf Corporation Composition de revetement d’enduit lustre
EP2139483B9 (fr) * 2007-04-11 2014-05-21 Exelixis, Inc. Therapies combinatoires comprenant un inhibiteur de pi3k-alpha de type quinaxoline pour leur utilisation dans le traitement du cancer
WO2010146391A1 (fr) * 2009-06-15 2010-12-23 Generics [Uk] Limited Synthèse régiosélective de létrozole
WO2012065057A2 (fr) * 2010-11-12 2012-05-18 Exelixis, Inc. Inhibiteurs de la phosphatidylinositol 3-kinase et leurs procédés d'utilisation

Also Published As

Publication number Publication date
BR112014005858A2 (pt) 2017-06-13
IN2014CN02671A (fr) 2015-07-03
IL231448A0 (en) 2014-04-30
WO2013040337A1 (fr) 2013-03-21
KR20140077911A (ko) 2014-06-24
TW201325592A (zh) 2013-07-01
AU2012308414A1 (en) 2014-05-01
UY34339A (es) 2013-04-30
EP2755654A1 (fr) 2014-07-23
WO2013040337A9 (fr) 2014-04-03

Similar Documents

Publication Publication Date Title
EP3601281B1 (fr) Formes cristallines de l'acide 4-(1-(1,1-di(pyridin-2-yl)éthyl)-6-(3,5-diméthylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoïque en tant que inhibiteur de bromodomaine
AU2008236562B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
EP2142544B1 (fr) Composés pyrido [2, 3-d]pyrimidin-7-one utilisés en tant qu'inhibiteurs de pi3k-alpha pour le traitement du cancer
TW201306842A (zh) 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CN105120868A (zh) 组合治疗
JP2010523677A (ja) 癌の治療のためのＰＩ３Ｋα阻害剤としてのピリド［２，３−Ｄ］ピリミジン−７−オン
KR20190058550A (ko) 병용 요법
WO2012149308A1 (fr) Méthode de traitement d'un lymphome à l'aide d'inhibiteurs de pyridopyrimidinone de pi3k/mtor
CA2848724A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer
WO2013056067A1 (fr) Composés pour une utilisation dans le traitement de carcinome des cellules basales
MX2011009413A (es) Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150915